ALLEGAN, Mich. — Perrigo Co. partner Cobrek Pharmaceuticals Inc. has received final approval from the Food and Drug Administration for betamethasone valerate foam (0.12%), a psoriasis medication.
Perrigo said Tuesday that it has manufactured the product, a generic version of Stiefel’s Luxiq Foam, and is set to begin commercial shipments on Jan. 15, consistent with the date certain launch settlement. Cobrek was first to file, making the product eligible for 180 days of marketing exclusivity.
Betamethasone valerate foam 0.12% is indicated for the relief of scalp psoriasis. Brand annual sales were approximately $40 million.
"This is our sixth product approval using a foam dosage form, which requires specialized development and manufacturing capabilities," stated Perrigo chairman and chief executive officer Joseph Papa. "It is an example of the excellent partnership we have with Cobrek, and we are committed to making quality health care more affordable for our customers."
